| ABSTRACT Objective:To study the curative effect and safety of Metformin with SGLT 2 inhibitor in treatment of type 2 diabetes mellitus (T2DM) patients with bad blood glucose control. Methods:90 cases of T2DM patients whose from our hospital which were randomly divided into two groups, 45 cases in each group. The patients in the observation group were treated by Dapagliflozin combining with Metformin, while in the control group they were treated by Glimepiride combining with Metformin. After 24 weeks of treatment, and the FPG, 2hPG, HbA1c and BMI changes in 24 weeks before and after treatment were observed, and occurrence frequency of hypoglycemia and other adverse reactions were compared between the two groups. Results:Both groups had better FPG, 2hPG and HbA1c than before treatment (P＜0.05), and both groups had no statistically significant difference (P>0.05). The effect of BMI of these patients after treatment in the observation group was evidently better than that in the control group, the difference had statistically significant (P<0.05). Hypoglycemia frequency in the observation group were obviously lower than those in the control group, the difference were statistically significant (P<0.05). Conclusion:After 24 weeks of treatment, adding Glimepiride or Dapagliflozin in poorly controlled T2DM patients with Metformin could control the glycemia effectively. The effect of Dapagliflozin combined with Metformin was obviously better than that of Glimepiride combined with Metformin therapy, which could improve the obesity, and reduce the hypoglycemia reactions. Dapagliflozin combined with Metformin was effective and safe in the treatment of T2DM patients. |
